How to Get Alprostadil (Caverject/MUSE) in California

What Is Alprostadil and Why California Patients Use It

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum, increases arterial inflow, and produces an erection independent of psychogenic or neurogenic sexual stimulation. Because it works through a direct vascular mechanism rather than through the nitric-oxide/PDE5 pathway, it succeeds where oral PDE5 inhibitors (sildenafil, tadalafil) fail. The FDA approved Caverject for intracavernosal injection in 1995 and MUSE (medicated urethral system for erection) for intraurethral delivery in 1996. FDA label reference is at accessdata.fda.gov.

The landmark Linet et al. trial published in the New England Journal of Medicine (N=683) showed that alprostadil intracavernosal injection produced erections sufficient for intercourse in 94.8% of injection attempts, compared with 13.8% in the placebo group (Linet, NEJM 1996). That 81-percentage-point separation between active drug and placebo remains one of the largest treatment-effect sizes in erectile dysfunction pharmacology.

California has roughly 3.8 million men with erectile dysfunction, based on age-standardized prevalence data from the CDC's National Health Interview Survey. CDC NHIS data is available here. Approximately 30 to 40% of those men do not respond adequately to oral PDE5 inhibitors, making alprostadil a clinically meaningful second-line or third-line option per American Urological Association guidelines. AUA ED guideline is published at pubmed.ncbi.nlm.nih.gov.

How Alprostadil Works: ICI vs. MUSE

The two FDA-approved delivery routes produce meaningfully different efficacy and side-effect profiles, and choosing between them affects which pharmacy and prescriber pathway makes sense in California.

Intracavernosal injection (Caverject, generic alprostadil ICI). A fine-gauge needle delivers 2.5 to 40 mcg directly into the corpus cavernosum. Onset is 5 to 10 minutes. The Linet NEJM trial reported a 31.2% rate of penile pain with active drug vs. 13.3% placebo. Linet 1996 full text, NEJM. Priapism (erection lasting more than 4 hours) occurred in 1.0% of patients in that cohort, requiring clinical management. Dose titration must occur in a clinical setting on the first one to three occasions before home self-injection.

Intraurethral suppository (MUSE). A 125 to 1 to 000 mcg pellet is placed 3 cm into the urethra using a plastic applicator. Bioavailability is lower than ICI; a Padma-Nathan et al. study (N=1,511) found that 64.9% of MUSE-treated men achieved at least one erection sufficient for intercourse in a home setting, versus 18.6% placebo. Padma-Nathan, NEJM 1997. MUSE avoids needles entirely, which improves adherence for needle-averse patients. Urethral burning is the most common complaint, reported in 35% of treated men in that trial.

Both formulations are approved for erectile dysfunction of vasculogenic, neurogenic, psychogenic, or mixed etiology. FDA drug label details, accessdata.fda.gov.

Getting a Prescription in California: Step-by-Step

California law permits alprostadil prescriptions from any licensed prescriber who has established a valid patient-provider relationship. That relationship can be established via synchronous audiovisual telehealth under California Business and Professions Code Section 2290.5. There is no requirement for a prior in-person visit before prescribing alprostadil via telehealth, provided the prescriber documents a thorough history, reviews relevant labs, and confirms the diagnosis of erectile dysfunction. California BPC 2290.5, full text via California Legislative Information.

Step 1. Schedule a medical evaluation. This may be in-person (urologist, primary care, men's health clinic) or via a telehealth platform licensed in California. The evaluation covers sexual history, duration and severity of ED, cardiovascular risk factors, and medication list.

Step 2. Provide baseline labs. Most prescribers order total testosterone, free testosterone, CBC, metabolic panel, fasting glucose or HbA1c, and a lipid panel before initiating alprostadil. These confirm no underlying hypogonadism driving ED and establish cardiovascular risk. Endocrine Society hypogonadism guideline, pubmed.ncbi.nlm.nih.gov. The International Index of Erectile Function (IIEF) questionnaire may be administered to establish a baseline severity score. IIEF validation, pubmed.ncbi.nlm.nih.gov.

Step 3. In-office or virtual dose titration. For ICI, the first dose (2.5 mcg) is given under clinical supervision to observe for priapism and cardiovascular response. MUSE patients may receive the first dose in clinic or at home at 250 mcg with instructions to escalate if needed. AUA ED clinical guideline, pubmed.ncbi.nlm.nih.gov.

Step 4. Receive the prescription. Once titrated, the prescriber sends the Rx to a retail pharmacy (Walgreens, CVS, Costco) or a licensed California 503A compounding pharmacy. Caverject Impulse 10 mcg and 20 mcg dual-chamber systems are the most commonly dispensed brand products.

Step 5. Obtain injection training. Self-injection technique reduces complications. Studies show a complication rate below 5% in trained patients vs. approximately 20% in untrained patients for penile fibrosis or hematoma. Montorsi et al., pubmed.ncbi.nlm.nih.gov.

Telehealth Providers Prescribing Alprostadil in California

Several telehealth platforms are licensed to practice in California and routinely prescribe alprostadil. California's telehealth parity law (AB 744, 2016) requires commercial insurers to reimburse telehealth services at the same rate as in-person visits, which has expanded provider availability statewide. AB 744 legislative history, California Legislative Information.

A synchronous video visit takes 20 to 40 minutes. The prescriber reviews prior PDE5 inhibitor trials (documenting refractory status for insurance purposes), assesses penile anatomy via patient self-examination instructions, and reviews labs uploaded by the patient. Prescriptions can be sent electronically to any California-licensed pharmacy.

HealthRX offers California telehealth consultations for alprostadil. After a video visit, most patients receive an e-prescription within 24 hours and medication within 3 to 7 business days through a partnered 503A pharmacy.

For patients who have never used alprostadil, the prescriber may start with MUSE to avoid the needle-training barrier, then transition to ICI if MUSE efficacy is inadequate. A crossover study by Costabile et al. showed that patients who switched from MUSE to ICI reported significantly higher satisfaction (67% vs. 41%, P<0.05). Costabile et al., pubmed.ncbi.nlm.nih.gov.

Labs Required Before Alprostadil in California

Most California prescribers follow the AUA's Sexual Medicine guideline panel recommendation that baseline hormonal and metabolic labs be obtained before initiating any ED pharmacotherapy. AUA sexual medicine guideline, pubmed.ncbi.nlm.nih.gov. The standard panel includes:

• Total testosterone (morning draw, 7 to 10 a.m.)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH if total testosterone is below 300 ng/dL
• HbA1c or fasting glucose (diabetes is the single largest modifiable risk factor for ED; prevalence in men with ED is 35 to 50% per ADA data) ADA Standards of Care, diabetesjournals.org
• Fasting lipid panel
• PSA (for men over 40 if concomitant testosterone therapy is being considered)
• CBC and CMP

Telehealth platforms typically accept results from any CLIA-certified lab in California. Quest Diagnostics and LabCorp have more than 400 combined draw sites across the state.

Compounding Alprostadil in California: 503A Pharmacy Rules

Brand-name Caverject carries a list price above $80 per single-use vial. Compounded alprostadil from a 503A pharmacy can reduce per-dose cost to $15 to $35, depending on the formulation and volume ordered. California 503A pharmacies operate under both federal FDCA Section 503A rules and state oversight by the California State Board of Pharmacy (CSBP). CSBP regulations, pharmacy.ca.gov.

A 503A pharmacy must receive a patient-specific prescription from a licensed California prescriber. It may not manufacture alprostadil in large sterile batches without first receiving a valid Rx. Compounded alprostadil ICI is typically prepared as a 20 mcg/mL or 40 mcg/mL solution in bacteriostatic water or sodium chloride, dispensed in multi-dose vials. Stability data supports a 30-day shelf life when refrigerated at 2 to 8°C. USP <797> sterile compounding standards, pubmed.ncbi.nlm.nih.gov.

Some California compounding pharmacies also prepare Tri-Mix (alprostadil + papaverine + phentolamine) and Bi-Mix formulations. These are not FDA-approved products; the prescriber assumes clinical responsibility for off-label compounded use. A meta-analysis by Yuan et al. (N=2,286 across 14 trials) found that Tri-Mix produced erection rates of 92% and was better tolerated than alprostadil monotherapy in men with severe vascular ED. Yuan et al., pubmed.ncbi.nlm.nih.gov.

Medi-Cal (California Medicaid) Coverage and Prior Authorization

Medi-Cal covers alprostadil for refractory erectile dysfunction with prior authorization. "Refractory" in this context means documented failure of at least one oral PDE5 inhibitor at adequate dosing. The Medi-Cal pharmacy manual specifies that the PA request must include diagnosis code N52.01 to N52.9 (male erectile dysfunction) and documentation of PDE5 inhibitor trial. Medi-Cal pharmacy manual, dhcs.ca.gov.

The documentation package for a Medi-Cal PA typically contains:

1. A letter of medical necessity on prescriber letterhead
2. Records showing PDE5 inhibitor use (dose, duration, and reason for failure)
3. Relevant lab results confirming no untreated hormonal cause
4. An IIEF-5 score below 21 (indicating at least mild ED) IIEF-5 validation study, pubmed.ncbi.nlm.nih.gov
5. Any contraindications to oral therapy (e.g., nitrate use, hypotension)

Processing time under Medi-Cal is 3 to 5 business days for standard PA and 24 hours for urgent PA. Covered Medi-Cal plans include fee-for-service and managed care plan (MCP) contracts; patients should confirm their specific plan's formulary tier.

Commercial insurance coverage varies. Covered California benchmark plans are not required to cover alprostadil, but many PPO plans cover it at the specialty tier with a copay of $50 to $150 per kit. Patients should request a formulary exception if alprostadil is not listed. Covered California formulary requirements, coveredca.com.

Who Can Prescribe Alprostadil in California

California allows multiple prescriber types to write alprostadil Rx orders, each under their respective scope of practice:

Physicians (MD/DO). Any California-licensed MD or DO with prescriptive authority may prescribe alprostadil without restriction. Urologists and men's health specialists are most common, but primary care physicians prescribe it routinely.

Nurse Practitioners (NPs). California NPs with a valid Nurse Practitioner Furnishing Number (NPFN) issued by the California Board of Registered Nursing may independently furnish alprostadil. Since AB 890 (2020) went into effect in 2023 for NPs meeting practice requirements, independent practice NPs no longer require a supervising physician for prescribing. AB 890, California BRN bulletin.

Physician Assistants (PAs). California PAs may prescribe alprostadil under a PA practice agreement with a supervising physician. After SB 697 (2022), PAs may apply for an expanded practice agreement that allows greater independent prescribing. SB 697, California PA Board.

Pharmacist Prescribing. California pharmacists may prescribe certain medications under a Collaborative Practice Agreement (CPA), but alprostadil is not currently on the self-administered hormonal contraceptive or other statewide protocol lists. A site-specific CPA with a physician would be required. This pathway is rarely used for alprostadil in practice.

Transferring an Existing Alprostadil Prescription to California

Patients relocating to California from another state can transfer an existing retail pharmacy prescription if the original pharmacy is part of a national chain (e.g., CVS, Walgreens, Rite Aid). Federal law and California Business and Professions Code Section 4076 permit prescription transfers between licensed pharmacies for non-controlled drugs. Alprostadil is not a controlled substance. BPC 4076, California Legislative Information.

For compounded alprostadil from an out-of-state 503A pharmacy, the patient needs a new prescription from a California-licensed prescriber because the compounding pharmacy must receive a California-valid Rx. Out-of-state 503A pharmacies may ship into California only if they hold a California non-resident pharmacy license issued by the CSBP. CSBP non-resident pharmacy license info, pharmacy.ca.gov.

A new telehealth visit in California typically takes one consultation to re-establish clinical status and generate a new Rx. If the patient carries prior records (labs, prior prescriber notes, dose history), the visit is often 20 to 30 minutes.

Dosing Reference: Alprostadil ICI and MUSE

Prescribers in California follow FDA-labeled dosing with individualized titration. Published clinical trials and the AUA guideline inform these ranges. AUA ED guideline, pubmed.ncbi.nlm.nih.gov.

Caverject (ICI) dosing:

• Starting dose in clinic: 2.5 mcg
• Titration: increase by 2.5 to 5 mcg per session until adequate erection (sufficient for intercourse, lasting no more than 60 minutes)
• Typical effective home dose range: 10 to 20 mcg for psychogenic ED; 20 to 40 mcg for vasculogenic ED
• Maximum single dose: 40 mcg
• Frequency: no more than 3 times per week, with at least 24 hours between doses
• Storage: refrigerate at 2 to 8°C before reconstitution; use within 24 hours after mixing

MUSE dosing:

• Starting dose: 250 mcg intraurethral
• Titration: may increase to 500 mcg or 1 to 000 mcg if inadequate response
• Frequency: no more than 2 doses per 24 hours
• Administration: urinate before use (lubricates urethra), insert applicator 3 cm, release pellet, roll penis 10 seconds

The Linet NEJM 1996 trial showed that 4.0% of Caverject-treated patients required treatment for prolonged erection vs. 0% in placebo. Linet, NEJM 1996. Patients should be counseled that erections persisting beyond 4 hours require emergency care. An intracavernous injection of phenylephrine 200 mcg is the first-line reversal agent per AUA protocol. AUA priapism guideline, pubmed.ncbi.nlm.nih.gov.

Contraindications and Drug Interactions

Alprostadil is contraindicated in men with:

• Hypersensitivity to alprostadil or any component of the formulation
• Conditions predisposing to priapism: sickle cell disease, sickle cell trait, multiple myeloma, leukemia
• Penile anatomical deformity (severe Peyronie's disease with greater than 30-degree curvature) that increases injection risk
• Penile implants (ICI is contraindicated; MUSE is relatively contraindicated)
• Urethral stricture or balanitis (MUSE only)

Concomitant use with anticoagulants (warfarin, apixaban, rivaroxaban) increases hematoma risk at the injection site. A 2019 case series in the Journal of Sexual Medicine reported ecchymosis in 6 of 12 men on direct oral anticoagulants who used ICI without technique modification. Alprostadil and anticoagulants, pubmed.ncbi.nlm.nih.gov.

Alprostadil does not interact with nitrates. Men taking nitrate medications for cardiovascular conditions can use alprostadil safely, which is a key clinical advantage over PDE5 inhibitors. FDA drug interaction data, accessdata.fda.gov.

Monitoring After Starting Alprostadil

After the first home dose, patients should check in with their prescriber at 2 to 4 weeks. The visit covers:

• Dose efficacy (IIEF-5 re-assessment; a score increase of 4 or more points is considered clinically meaningful) IIEF-5 anchor-based MID, pubmed.ncbi.nlm.nih.gov
• Injection site inspection for nodules or fibrosis (palpable fibrosis occurs in up to 5% of chronic ICI users) Montorsi et al., pubmed.ncbi.nlm.nih.gov
• Systemic symptoms: dizziness, hypotension, urethral discomfort (MUSE)
• Adherence and technique review

Annual follow-up should include a lipid panel and HbA1c to monitor the underlying vascular disease driving ED in most patients. A prospective cohort published in JAMA Internal Medicine found that new-onset ED predicted major adverse cardiovascular events within 3 years in 12% of men under 60 (hazard ratio 1.6 after adjustment for traditional risk factors). Vlachopoulos et al., pubmed.ncbi.nlm.nih.gov.